(Press-News.org) Sophia Antipolis - 1 July 2021: Heart failure patients aged 80 and above are less likely to receive recommended therapies and dosages compared to their younger counterparts, according to research presented today at Heart Failure 2021, an online scientific congress of the European Society of Cardiology (ESC).1
"Guidelines recommend the same treatments for all heart failure patients regardless of age," said study author Dr. Davide Stolfo of the Karolinska Institute, Stockholm, Sweden.2 "Our analysis adjusted for other conditions that might justify withholding therapy or reducing the dose - for example impaired kidney function - and age was independently associated with undertreatment."
The study investigated the prescription of evidence-based therapy in patients with heart failure according to three age categories: under 70, 70 to 79, and 80 years or older. The analysis was limited to heart failure with reduced ejection fraction since it is the only subtype with treatments proven to benefit prognosis. The researchers used data from the nationwide Swedish Heart Failure Registry linked with other national registries in 2000 to 2018.
The study included 27,430 patients with heart failure. The average age was 74 years and 27% were women. Regarding the age categories, 31% were under 70, 34% were 70 to 79, and 35% were 80 years or above. Patients in the oldest age category were more likely to be women than men, and had more severe heart failure and more co-existing conditions compared to the other age groups.
Prescription of treatments progressively decreased with increasing age. Regarding medications, RASi (renin angiotensin system inhibitor)/ARNi (angiotensin receptor neprilysin inhibitor), beta-blockers, and MRA (mineralocorticoid receptor antagonist), respectively, were prescribed in 95%, 95% and 54% in patients aged under 70? 90%, 93% and 47% in patients aged 70 to 79; and 80%, 88% and 35% in those aged 80 or above.
Regarding device therapies, the use of implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation therapy (CRT), respectively, among eligible patients was 22% and 50% in patients under 70; 17% and 42% in the 70 to 79 group; and 5% and 23% in those aged 80 or above.
Patients aged 80 or above were also less likely to be treated with the recommended dose of medications or to receive all three recommended types of medications (RASi/ARNI, beta-blocker and MRA). Half of those under 70 met both recommendations compared to just 42% of the 70 to 79 age group, and 26% of those aged 80 or above.
The researchers analysed the association of age with the prescription of each medication and device, and the use of recommended doses. The analysis was extensively adjusted for other conditions including diabetes, previous cancer, kidney function, low blood pressure and anaemia. With the exception of CRT, age was independently and inversely associated with the odds of receiving recommended treatments and dosages.
Dr. Stolfo said: "Our analysis shows that even after statistical adjustment for many other variables included in the registries, nearly all treatments are underused in older patients. This was an observational study so it is not possible to determine the reasons, but one possibility is that clinicians believe treatments are less effective in older people with heart failure."
Dr. Stolfo noted that older patients, particularly those with co-existing conditions, are often excluded from clinical trials. He said: "Studies in older age groups with heart failure are needed to provide clinicians with greater certainty about the effectiveness of full-dose treatment. We should follow the example of a study investigating this question according to gender, which suggested that women with heart failure might need lower doses of some medications than men."3
He concluded: "In younger patients with heart failure, the primary goal of treatment is to improve survival, while in older patients we aim to reduce symptoms, improve quality of life and prevent hospitalisations. Strategies are needed to ensure that all patients with heart failure are optimally treated."
INFORMATION:
Authors: ESC Press Office
Tel: +33 (0)4 89 87 20 85
Mobile: +33 (0)7 8531 2036
Email: press@escardio.org
Follow us on Twitter @ESCardioNews
Notes to editor
Funding: This was an investigator initiated study supported by Boehringer Ingelheim.
Disclosures: Dr. Stolfo reports personal fees from Novartis, Merck, GSK and Acceleron.
References and notes
1Abstract title: Use of heart failure evidence-based therapy across age strata: data from the Swedish Heart Failure Registry.
2Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37:2129-2200.
3Santema BT, Ouwerkerk W, Tromp J, et al. Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. Lancet. 2019;394:1254-1263.
About Heart Failure 2021 & World Congress on Acute Heart Failure
Heart Failure is the annual congress of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
#HeartFailure2021
About the Heart Failure Association
The Heart Failure Association (HFA) is a branch of the European Society of Cardiology (ESC). Its aim is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
About the European Society of Cardiology
The European Society of Cardiology brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.
Information for journalists about registration for Heart Failure 2021
Heart Failure 2021 takes place held 29 June to 1 July online. Explore the scientific programme.
Free registration applies only to accredited press.
Credentials: A valid press card or appropriate letter of assignment with proof of three recent published articles (cardiology or health-related or referring to a previous ESC event). Read the ESC media and embargo policy.
The ESC Press Office will verify the documents and confirm by email that your press accreditation is valid.
The ESC Press Office decision is final regarding all press registration requests.
As the COVID-19 pandemic exploded across the globe in early 2020, the world's leaders were faced with a flurry of tough moral dilemmas. Should schools and businesses shut down, and if so, for how long? Who should receive scarce resources, such as ventilators, when there wouldn't be enough for everyone? Should people be required to practice contact tracing to control the spread of infection? Should life-saving medicine be held for a country's own citizens or shared with those in greater need?
Some global leaders advocated for a utilitarian approach to these dilemmas: impartially maximizing the greatest good for the greatest number of people, even if that would come at the cost of harming a minority of the population. Utilitarianism, however, is a controversial ...
1 July 2021: Despite only limited evidence that fertility add-ons increase the odds of having a baby, the majority of women (82%) have used one or more of these treatments as part of their IVF.
This is the conclusion of a retrospective study of 1,590 Australian patients which also found more than seven in 10 (72%) had incurred additional costs for these unproven additional therapies and techniques which range from Chinese herbal medicine to endometrial scratching.
The results based on an online survey into prevalence of these optional extras will be presented today by principal investigator Dr Sarah Lensen, a researcher from the University of Melbourne, Australia, at the 37th virtual Annual Meeting of ESHRE.
The findings, says Lensen, suggest ...
Bottom Line: For women diagnosed with breast cancer in Florida, breast cancer-specific mortality rates have decreased more among Black and Hispanic women than white women since 1990. Despite these advances, Black women still have double the five- and 10-year mortality rates of non-Hispanic white women.
Journal in Which the Study was Published: Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.
Author: Robert Hines, PhD, MPH, associate professor of population health sciences at the University of ...
Evidence shows significant reduction in indicators of potential harm over 6-months for smokers switching to exclusive use of glo compared with continuing to smoke cigarettes
Gold-standardi indicator supports scientific substantiation of glo's potential as a reduced risk product*
First ever long-term study showing sustained reduction in exposure to certain toxicants and indicators of potential harm in smokers switching completely to glo
Supports BAT's delivery of A Better TomorrowTM by reducing the health impact of its global business by encouraging ...
New research from marine biologists offers answers to a fundamental puzzle that had until now remained unsolved: why are some fish warm-blooded when most are not?
It turns out that while (warm-blooded) fish able to regulate their own body temperatures can swim faster, they do not live in waters spanning a broader range of temperatures.
The research therefore provides some of the first direct evidence as to the evolutionary advantage of being warm-blooded as well as underlining that species in this demographic - such as the infamous white shark and the speedy bluefin tuna - are likely just as vulnerable to changing ...
Nanosized molecules of a particular chemical element can inhibit the formation of plaque in the brain tissues. This new discovery by researchers at Umeå University, Sweden, in collaboration with researchers in Croatia and Lithuania, provides renewed hope for novel treatments of, for instance, Alzheimer's and Parkinson's disease in the long run.
"This is indeed a very important step that may form the basis of new and efficient treatments of neurodegenerative diseases in the future," says Professor Ludmilla Morozova-Roche at Umeå University.
When proteins misfold they form insoluble fibrils called amyloids, which are involved in several serious diseases such as Alzheimer's and Parkinson's, Corino de Andrade's and the mad cow ...
SAN ANTONIO (June 30, 2021) -- In a U.S. and Swiss study, nearly all patients with cancer developed good immune response to the COVID-19 mRNA vaccines three to four weeks after receiving their second dose, but the fact that a small group of the patients exhibited no response raised questions about how their protection against the virus will be addressed moving forward.
Among the 131 patients studied, 94% developed antibodies to the coronavirus. Seven high-risk patients did not. "We could not find any antibodies against the virus in those patients," said Dimpy P. Shah, MD, PhD, of the Mays Cancer Center, home to UT Health San Antonio MD Anderson. "That has implications for the future. Should we provide a third dose of vaccine after cancer therapy has completed ...
Expanding symptom list in line with other countries could improve the UK's pandemic response
The UK should expand its official list of symptoms for defining covid-19 to prevent cases being missed and help improve the UK's pandemic response, say experts in The BMJ today.
They argue that limiting symptomatic testing to those with these official symptoms "will miss or delay identification of many covid-19 cases, hampering efforts to interrupt transmission."
During the covid-19 pandemic the British public has been told to self-isolate and get a test if they have a high fever, a new continuous cough, or ...
Eating a diet rich in omega 3 (n-3) fatty acids reduces the frequency of headaches compared with a diet with normal intake of omega 3 and omega 6 (n-6) fatty acids, finds a study published by The BMJ today.
Modern industrialised diets tend to be low in omega 3 fatty acids and high in omega 6 fatty acids. These fatty acids are precursors to oxylipins - molecules involved in regulating pain and inflammation.
Oxylipins derived from omega 3 fatty acids are associated with pain-reducing effects, while oxylipins derived from omega 6 fatty acids worsen pain and can provoke migraine. But previous studies evaluating omega 3 fatty acid supplements for migraine have been inconclusive.
So a team of US researchers wanted to find out whether diets ...
A diet higher in fatty fish helped frequent migraine sufferers reduce their monthly number of headaches and intensity of pain compared to participants on a diet higher in vegetable-based fats and oils, according to a new study. The findings by a team of researchers from the National Institute on Aging (NIA) and the National Institute on Alcohol Abuse and Alcoholism (NIAAA), parts of the National Institutes of Health; and the University of North Carolina (UNC) at Chapel Hill, were published in the July 3 issue of The BMJ.
This study of 182 adults with frequent migraines ...
